Clinical trial
In Which Tumor Burden Range Does Advanced Hepatocellular Carcinoma Patients Benefit More from Hepatic Arterial Infusion Chemotherapy Plus Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors Than Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors? a Multi-center, Retrospective, Propensity Score Matching Study
NCT06632106 is registered in ClinicalTrials.gov with First Hospital of China Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- In Which Tumor Burden Range Does Advanced Hepatocellular Carcinoma Patients Benefit More from Hepatic Arterial Infusion Chemotherapy Plus Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors Than Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors? a Multi-center, Retrospective, Propensity Score Matching Study
- Lead sponsor
- First Hospital of China Medical University
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- August 16, 2024
- Completion date
- May 30, 2025
- Enrollment
- 97 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hepatic arterial infusion chemotherapy, hepatocellular carcinoma (hcc), immune checkpoint inhibitors, tyrosine kinase inhibitor